Postmenopausal Osteoporosis [PDF]
openaire +1 more source
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. [PDF]
Leder BZ +6 more
europepmc +1 more source
Value of serum uric acid in a risk prediction model for postmenopausal osteoporosis. [PDF]
Li B, Ye Y, Li J.
europepmc +1 more source
GLP-2 alleviates postmenopausal osteoporosis by acting on osteoblasts through the PI3K/AKT/FOXO1 signalling pathway to downregulate FGF23 expression. [PDF]
Wu K, Ren W, Xu B, Shen J, Xu K, Hu Y.
europepmc +1 more source
BPAG1 promotes osteoclastogenesis and postmenopausal osteoporosis via activating ERK signaling pathway. [PDF]
Zhang Y +4 more
europepmc +1 more source
Efficacy of Statins in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis. [PDF]
Biswas P +2 more
europepmc +1 more source
Nanoparticles coated with osteoblast-like cell membranes as curcumin delivery vehicles for targeted postmenopausal osteoporosis therapy. [PDF]
Li Q +6 more
europepmc +1 more source
The impact of DXA findings on general practitioners' decision regarding first-line oral bisphosphonates in postmenopausal osteoporosis-data from French General Practice (the IMOGENE study). [PDF]
Cortet B +4 more
europepmc +1 more source
Dendrobine promotes bone formation via the canonical Wnt/β-catenin signaling pathway and prevents postmenopausal osteoporosis. [PDF]
Li S +5 more
europepmc +1 more source
Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial. [PDF]
Wang H +5 more
europepmc +1 more source

